Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Intravitreal thalidomide reduces experimental preretinal neovascularisation without induction of retinal toxicity.

Vom Hagen F, Kamppeter BA, Erber R, Jonas JB, Hammes HP.

Br J Ophthalmol. 2010 Apr;94(4):504-8. doi: 10.1136/bjo.2009.158790. Epub 2009 Aug 27.

PMID:
19713194
2.

Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye.

Kamppeter BA, Cej A, Jonas JB.

Ophthalmology. 2008 Aug;115(8):1372-5. doi: 10.1016/j.ophtha.2008.01.019. Epub 2008 Mar 20.

PMID:
18355920
3.

Visual acuity change after intravitreal triamcinolone in various types of exudative age-related macular degeneration.

Jonas JB, Strueven V, Kamppeter BA, Harder B, Spandau UH, Schlichtenbrede F.

J Ocul Pharmacol Ther. 2006 Oct;22(5):370-6.

PMID:
17076632
4.

Bevacizumab for occult subfoveal neovascularization in age-related macular degeneration.

Jonas JB, Harder B, Spandau UH, Kamppeter BA, Libondi T, Sauder G.

Eur J Ophthalmol. 2006 Sep-Oct;16(5):774-5.

PMID:
17061237
5.

Repeated intravitreal injection of triamcinolone for exudative age-related macular degeneration.

Jonas JB, Spandau UH, Kamppeter BA, Vossmerbaeumer U, Harder B.

Ophthalmic Res. 2006;38(6):324-8. Epub 2006 Oct 13.

PMID:
17047404
6.

Further investigation of the tolerance and mechanical adjustability of the *Acri.Tec AR-1 PC/IOL in rabbit eyes: an intraocular lens with reversibly adjustable optical power.

Jahn CE, Fromberg I, Fesser N, Allgoewer I, Jahn CH, Wakili NS, Hofmann-Rummelt CR, Holbach LM, Kamppeter BA.

Ophthalmic Res. 2006;38(5):309-12. Epub 2006 Sep 15.

PMID:
16974133
7.

Follow-up after intravitreal triamcinolone acetonide for diabetic macular edema.

Jonas JB, Spandau UH, Kamppeter BA, Vossmerbaeumer U, Harder B.

Eur J Ophthalmol. 2006 Jul-Aug;16(4):566-72.

PMID:
16952096
8.

Triamcinolone acetonide-induced ocular hypertension.

Jonas JB, Sauder G, Budde WM, Spandau UH, Kamppeter BA, Harder B.

J Ocul Pharmacol Ther. 2006 Aug;22(4):247-50.

PMID:
16910865
9.

Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study.

Jonas JB, Kamppeter BA, Harder B, Vossmerbaeumer U, Sauder G, Spandau UH.

J Ocul Pharmacol Ther. 2006 Jun;22(3):200-7.

PMID:
16808682
10.

Duration of the effect of intravitreal triamcinolone acetonide in eyes with exudative age-related macular degeneration.

Jonas JB, Spandau UH, Kamppeter BA, Degenring RF, Kreissig I, Akkoyun I, Vossmerbaeumer U.

J Ocul Pharmacol Ther. 2006 Jun;22(3):194-9.

PMID:
16808681
11.

Optical coherence tomography of the optic nerve head: interindividual reproducibility.

Kamppeter BA, Schubert KV, Budde WM, Degenring RF, Jonas JB.

J Glaucoma. 2006 Jun;15(3):248-54.

PMID:
16778649
12.

[Acute vision loss in oculus ultimus].

Kamppeter BA, Jonas JB, Degenring RF.

Ophthalmologe. 2007 May;104(5):418-21. German. No abstract available.

PMID:
16738873
13.

Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema.

Jonas JB, Spandau UH, Kamppeter BA, Vossmerbaeumer U, Harder B, Sauder G.

Ophthalmology. 2006 May;113(5):800-4. Epub 2006 Mar 13.

PMID:
16530840
14.

Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration.

Jonas JB, Spandau UH, Kamppeter BA, Harder B.

Eye (Lond). 2007 Mar;21(3):387-94. Epub 2006 Jan 13.

PMID:
16410809
15.

Dynamic contour tonometry for intraocular pressure measurement.

Kamppeter BA, Jonas JB.

Am J Ophthalmol. 2005 Aug;140(2):318-20.

PMID:
16086958
16.
17.

Contrast and glare sensitivity after implantation of AcrySof and Human Optics 1CU intraocular lenses.

Kamppeter BA, Sauder G, Jonas JB.

Eur J Ophthalmol. 2005 Jul-Aug;15(4):458-61.

PMID:
16001377
18.
19.

Intraocular pressure elevation after intravitreal triamcinolone acetonide injection.

Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA.

Ophthalmology. 2005 Apr;112(4):593-8.

PMID:
15808249
20.

Intravitreal triamcinolone acetonide and central serous chorioretinopathy.

Jonas JB, Kamppeter BA.

Br J Ophthalmol. 2005 Mar;89(3):386-7. No abstract available.

21.

Inter-eye difference in diabetic macular edema after unilateral intravitreal injection of triamcinolone acetonide.

Jonas JB, Harder B, Kamppeter BA.

Am J Ophthalmol. 2004 Dec;138(6):970-7.

PMID:
15629288
22.

Repeated intravitreal injection of triamcinolone acetonide for diffuse diabetic macular oedema.

Jonas JB, Kreissig I, Degenring RF, Kamppeter BA.

Br J Ophthalmol. 2005 Jan;89(1):122. No abstract available.

23.

Chronic prephthisical ocular hypotony treated by intravitreal triamcinolone acetonide.

Jonas JB, Vossmerbaeumer U, Kamppeter BA.

Acta Ophthalmol Scand. 2004 Oct;82(5):637. No abstract available.

24.

Optical coherence tomography of a peripheral retinal schisis with an outer retinal layer break.

Kamppeter BA, Jonas JB.

Acta Ophthalmol Scand. 2004 Oct;82(5):574-5. No abstract available.

25.

Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema.

Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I.

Am J Ophthalmol. 2004 Jul;138(1):158-60.

PMID:
15234306
26.

Outcome of eyes undergoing trabeculectomy after intravitreal injections of triamcinolone acetonide.

Jonas JB, Degenring RF, Kamppeter BA.

J Glaucoma. 2004 Jun;13(3):261. No abstract available.

PMID:
15118474
27.

Intraocular lens with reversibly adjustable optical power: pilot study of concept and safety.

Jahn CE, Jahn MA, Kreiner CF, Serester A, Fromberg I, Jacobi S, Deutschmann S, Schäffer EH, Kamppeter BA.

J Cataract Refract Surg. 2003 Sep;29(9):1795-9.

PMID:
14522304

Supplemental Content

Loading ...
Support Center